Creation of the spin-off EPICS Therapeutics

The spin-off founded by François Fuks (Faculty of Medicine, U-CRC Director) will explore the potential of RNA changes seen in cancers to develop new drugs. EPICS Therapeutics raised funds of 7.2M € to initiate the first steps of the development of molecules targeting RNA-modifying enzymes. The company is headed by Jean Combalbert (former CEO of Ogeda).